GLYC News and Press, GlycoMimetics Inc. From 03/02/21

GlycoMimetics, Inc. (GLYC) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Chief Financial Officer Eric Feldman - Chief Medical Officer (Incoming) Conference Call Participants Ze...

GlycoMimetics (GLYC): Q4 GAAP EPS of -$0.32 in-line.Revenue of $0.16M misses by $0.04M.Press Release For further details see: GlycoMimetics EPS in-line, misses on revenue

Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Enrollment in 2021 is expected to support a planned interim analy...

Biotech Penny Stocks To Watch Right Now February closed out with a tumultuous week of trading in more than just penny stocks . Fears of inflation and uncertainty about the final stimulus plan triggered large sell-offs last week. Whether you were looking at small-caps or broader sect...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investor...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic part...

GlycoMimetics ([[GLYC]] -10.0%) promoted Eric Feldman, M.D., to SVP and Chief Medical Officer; Dr. Feldman joined the company in 2019 and was earlier VP, Global Clinical Development."Eric is internationally recognized for his work in the development of new therapies for the tre...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recogniz...

FOSTER CITY, Calif. and HANGZHOU, China and GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announc...

GlycoMimetics (NASDAQ:GLYC) announces new data supporting the statistically significant effects of rivipansel in acute vaso-occlusive crisis in patients with sickle cell disease.The data from the OLE efficacy analysis, presented at ASH, together with more extensive data from the previously-re...